Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260400 | 0.86 | EPHX2 (0.75) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5465081 | 0.81 | KMT2A (0.61) | EPHX2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5468451 | 0.80 | MEN1 (0.56) | EPHX2ALDH1A1MEN1KMT2AP2RX7 | |
| SCHEMBL4983338 | 0.78 | SIGMAR1 (0.55) | EPHX2CYP2C9POLBKDM4EALDH1A1 | |
| SCHEMBL16269121 | 0.78 | P2RX7 (0.53) | EPHX2CYP2C9POLBKDM4EALDH1A1 | |
| SCHEMBL5471711 | 0.77 | PKM (0.69) | KDM4EMEN1KMT2A | |
| SCHEMBL16269460 | 0.76 | EPHX2 (0.56) | EPHX2CYP2C9KDM4EALDH1A1CYP3A4 | |
| SCHEMBL5471150 | 0.76 | MEN1 (0.75) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5464853 | 0.76 | MEN1 (0.70) | EPHX2KDM4EMEN1KMT2AP2RX7 | |
| SCHEMBL5476543 | 0.75 | MEN1 (0.56) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | EPHX2 2049/4885CYP2C9 3124/4885POLB 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.